首页 > 最新文献

Fundamental & Clinical Pharmacology最新文献

英文 中文
Wnt/beta-catenin modulation: A promising frontier in chronic kidney disease management. Wnt/beta-catenin 调节:慢性肾病治疗的一个前景广阔的领域。
IF 2.1 4区 医学 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2024-08-05 DOI: 10.1111/fcp.13031
Shubhangi Saxena, Neha Dagar, Vishwadeep Shelke, Bhupendra Puri, Anil Bhanudas Gaikwad

Background: Being amongst the leading factors of death and distress, chronic kidney disease (CKD) has affected around 850 million people globally. The Wnt/β-catenin axis is vital for maintaining kidney homeostasis, from nephron generation to overall management. The β-catenin growth factor is typically not expressed in the adult kidney; however, its expression is found to increase under stress and injury conditions. It is categorised as canonical and non-canonical based on β-catenin availability, which mounts promising targets for ameliorating CKD. Hence, modulation of the Wnt/β-catenin signalling for CKD management is of utmost relevance.

Objectives: The primary aim of this review is to highlight the significance of targeting Wnt/β-catenin signalling for CKD management.

Methods: The literature review regarding the role of Wnt/β-catenin signalling and therapies modulating it in CKD was conducted using PubMed, Scopus, Science Direct and Google Scholar.

Results: The current review summarises the pharmacological therapies modulating the Wnt/β-catenin axis in CKD, building upon promising preclinical studies to establish a foundation for clinical studies in the future.

Conclusion: Wnt/β-catenin signalling is the evolution's most conserved pathway, which plays a pivotal role in CKD progression. Therapies modulating Wnt/β-catenin signalling have emerged as effective means for alleviating CKD.

背景:慢性肾脏病(CKD)是导致死亡和痛苦的主要因素之一,已影响到全球约 8.5 亿人。Wnt/β-catenin 轴对维持肾脏的平衡至关重要,包括肾小球的生成和整体管理。β-catenin生长因子通常不在成人肾脏中表达,但在压力和损伤条件下,其表达会增加。根据β-catenin的可用性,可将其分为典型和非典型两类,这为改善慢性肾脏病提供了有希望的靶点。因此,调节 Wnt/β-catenin 信号对治疗 CKD 至关重要:本综述的主要目的是强调靶向 Wnt/β-catenin 信号对治疗 CKD 的重要意义:方法:使用 PubMed、Scopus、Science Direct 和 Google Scholar 对 Wnt/β-catenin 信号在 CKD 中的作用以及调节 Wnt/β-catenin 信号的疗法进行文献综述:本综述总结了在 CKD 中调节 Wnt/β-catenin 轴的药理学疗法,以前景看好的临床前研究为基础,为未来的临床研究奠定基础:结论:Wnt/β-catenin 信号是进化过程中最保守的通路,在 CKD 的进展中起着关键作用。调节 Wnt/β-catenin 信号的疗法已成为缓解 CKD 的有效手段。
{"title":"Wnt/beta-catenin modulation: A promising frontier in chronic kidney disease management.","authors":"Shubhangi Saxena, Neha Dagar, Vishwadeep Shelke, Bhupendra Puri, Anil Bhanudas Gaikwad","doi":"10.1111/fcp.13031","DOIUrl":"https://doi.org/10.1111/fcp.13031","url":null,"abstract":"<p><strong>Background: </strong>Being amongst the leading factors of death and distress, chronic kidney disease (CKD) has affected around 850 million people globally. The Wnt/β-catenin axis is vital for maintaining kidney homeostasis, from nephron generation to overall management. The β-catenin growth factor is typically not expressed in the adult kidney; however, its expression is found to increase under stress and injury conditions. It is categorised as canonical and non-canonical based on β-catenin availability, which mounts promising targets for ameliorating CKD. Hence, modulation of the Wnt/β-catenin signalling for CKD management is of utmost relevance.</p><p><strong>Objectives: </strong>The primary aim of this review is to highlight the significance of targeting Wnt/β-catenin signalling for CKD management.</p><p><strong>Methods: </strong>The literature review regarding the role of Wnt/β-catenin signalling and therapies modulating it in CKD was conducted using PubMed, Scopus, Science Direct and Google Scholar.</p><p><strong>Results: </strong>The current review summarises the pharmacological therapies modulating the Wnt/β-catenin axis in CKD, building upon promising preclinical studies to establish a foundation for clinical studies in the future.</p><p><strong>Conclusion: </strong>Wnt/β-catenin signalling is the evolution's most conserved pathway, which plays a pivotal role in CKD progression. Therapies modulating Wnt/β-catenin signalling have emerged as effective means for alleviating CKD.</p>","PeriodicalId":12657,"journal":{"name":"Fundamental & Clinical Pharmacology","volume":null,"pages":null},"PeriodicalIF":2.1,"publicationDate":"2024-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141893247","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The therapeutic effect of NRF2 activator, ezetimibe, in cardiac cachexia. NRF2 激活剂依折麦布对心脏恶病质的治疗作用
IF 2.1 4区 医学 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2024-07-15 DOI: 10.1111/fcp.13029
Ruju Vashi, Mit Joshi, Bhoomika M Patel

Introduction: Heart failure (HF) is caused by functional and structural irregularity leading to impaired ejection or filling capacity of the heart. HF leads to chronic inflammatory conditions in the heart leads to weight loss, anorexia, and muscle atrophy known as cachexia. The present study was carried out to investigate the role of Ezetimibe, an NRF2 activator, in cardiac cachexia and to develop a treatment strategy for cardiac cachexia.

Method: Balb/c mice of either sex at 6-8 weeks of age were given 2 mg/kg of doxorubicin in 0.9% sodium chloride solution intraperitoneally (i.p.) for the alternate days for the first week and then once a week for the next 4 weeks. After induction of cardiac atrophy, treatment with Ezetimibe (1.5 mg/kg, p.o) was given for the next 4 weeks.

Result: In the cardiac cachectic animals, a significant decrease in body weight, food, and water intake was observed. Cardiac cachectic animals showed a significant increase in serum glucose, total cholesterol, LDL, triglyceride, VLDL, CK-MB, LDH, and CRP levels. Cardiac atrophic index, heart weight to body weight ratios (HW/BW), right ventricular weight to heart weight ratios (RV/HW), and left ventricular weight to heart weight ratios (LV/HW), were significantly decreased in cardiac cachectic animals. The weights of the skeletal muscles such as EDL, gastrocnemius, soleus, tibialis anterior, and quadriceps muscles, and the weight of adipose tissue such as subcutaneous, visceral, perirenal, and brown adipose tissue were significantly decreased in the cardiac cachectic group relative to the normal group. Treatment with ezetimibe improves body weight, food intake, and water intake. Ezetimibe decreases serum glucose, total cholesterol, LDL, triglyceride, VLDL, CK-MB, LDH and CRP levels. Cardiac atrophic markers such as HW/BW, RV/HW, and LV/HW were improved. The weight of skeletal muscles and adipose tissue was increased after treatment with ezetimibe.

Conclusion: Our data showed that the NRF2 activator, Ezetimibe produces a beneficial effect on cardiac cachexia in the doxorubicin-induced cardiac cachexia model. Ezetimibe was successful to reduce the levels of inflammatory cytokines, ameliorate the effects on cardiac muscle wasting, lipid levels, fat tissues, and skeletal muscles.

导言心力衰竭(HF)是由于功能和结构不正常导致心脏射血或充盈能力受损而引起的。心力衰竭会导致心脏慢性炎症,引起体重下降、厌食和肌肉萎缩,即恶病质。本研究旨在探究 NRF2 激活剂依折麦布在心脏恶病质中的作用,并制定心脏恶病质的治疗策略:方法:给 6-8 周龄的 Balb/c 小鼠腹腔注射 2 毫克/千克 0.9% 氯化钠溶液中的多柔比星,第一周隔天注射一次,随后 4 周每周注射一次。诱导心脏萎缩后,在接下来的 4 周内给予依折麦布(1.5 毫克/千克,口服)治疗:结果:观察到心脏萎缩动物的体重、进食量和饮水量显著下降。心脏衰竭动物的血清葡萄糖、总胆固醇、低密度脂蛋白、甘油三酯、VLDL、CK-MB、LDH 和 CRP 水平明显升高。心脏萎缩动物的心脏萎缩指数、心脏重量与体重之比(HW/BW)、右心室重量与心脏重量之比(RV/HW)和左心室重量与心脏重量之比(LV/HW)均明显下降。相对于正常组,心脏衰竭组的骨骼肌重量(如 EDL、腓肠肌、比目鱼肌、胫骨前肌和股四头肌)以及脂肪组织重量(如皮下组织、内脏组织、肾周组织和棕色脂肪组织)均明显降低。依折麦布治疗可改善体重、食物摄入量和水摄入量。依折麦布可降低血清葡萄糖、总胆固醇、低密度脂蛋白、甘油三酯、VLDL、CK-MB、LDH 和 CRP 水平。HW/BW、RV/HW 和 LV/HW 等心脏萎缩指标均有所改善。依折麦布治疗后,骨骼肌和脂肪组织的重量增加:我们的数据显示,在多柔比星诱导的心脏恶病质模型中,NRF2激活剂依折麦布对心脏恶病质产生了有益的影响。依泽替米贝成功降低了炎性细胞因子的水平,改善了对心肌消耗、血脂水平、脂肪组织和骨骼肌的影响。
{"title":"The therapeutic effect of NRF2 activator, ezetimibe, in cardiac cachexia.","authors":"Ruju Vashi, Mit Joshi, Bhoomika M Patel","doi":"10.1111/fcp.13029","DOIUrl":"https://doi.org/10.1111/fcp.13029","url":null,"abstract":"<p><strong>Introduction: </strong>Heart failure (HF) is caused by functional and structural irregularity leading to impaired ejection or filling capacity of the heart. HF leads to chronic inflammatory conditions in the heart leads to weight loss, anorexia, and muscle atrophy known as cachexia. The present study was carried out to investigate the role of Ezetimibe, an NRF2 activator, in cardiac cachexia and to develop a treatment strategy for cardiac cachexia.</p><p><strong>Method: </strong>Balb/c mice of either sex at 6-8 weeks of age were given 2 mg/kg of doxorubicin in 0.9% sodium chloride solution intraperitoneally (i.p.) for the alternate days for the first week and then once a week for the next 4 weeks. After induction of cardiac atrophy, treatment with Ezetimibe (1.5 mg/kg, p.o) was given for the next 4 weeks.</p><p><strong>Result: </strong>In the cardiac cachectic animals, a significant decrease in body weight, food, and water intake was observed. Cardiac cachectic animals showed a significant increase in serum glucose, total cholesterol, LDL, triglyceride, VLDL, CK-MB, LDH, and CRP levels. Cardiac atrophic index, heart weight to body weight ratios (HW/BW), right ventricular weight to heart weight ratios (RV/HW), and left ventricular weight to heart weight ratios (LV/HW), were significantly decreased in cardiac cachectic animals. The weights of the skeletal muscles such as EDL, gastrocnemius, soleus, tibialis anterior, and quadriceps muscles, and the weight of adipose tissue such as subcutaneous, visceral, perirenal, and brown adipose tissue were significantly decreased in the cardiac cachectic group relative to the normal group. Treatment with ezetimibe improves body weight, food intake, and water intake. Ezetimibe decreases serum glucose, total cholesterol, LDL, triglyceride, VLDL, CK-MB, LDH and CRP levels. Cardiac atrophic markers such as HW/BW, RV/HW, and LV/HW were improved. The weight of skeletal muscles and adipose tissue was increased after treatment with ezetimibe.</p><p><strong>Conclusion: </strong>Our data showed that the NRF2 activator, Ezetimibe produces a beneficial effect on cardiac cachexia in the doxorubicin-induced cardiac cachexia model. Ezetimibe was successful to reduce the levels of inflammatory cytokines, ameliorate the effects on cardiac muscle wasting, lipid levels, fat tissues, and skeletal muscles.</p>","PeriodicalId":12657,"journal":{"name":"Fundamental & Clinical Pharmacology","volume":null,"pages":null},"PeriodicalIF":2.1,"publicationDate":"2024-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141619758","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Bezafibrate mitigates oxidized-low density lipoprotein (ox-LDL)-induced the attachment of monocytes to endothelial cells: An implication in atherosclerosis 贝扎贝特可减轻氧化低密度脂蛋白(ox-LDL)诱导的单核细胞对内皮细胞的附着:对动脉粥样硬化的影响。
IF 2.1 4区 医学 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2024-07-15 DOI: 10.1111/fcp.13025
Huijun Huang, Yan Shen

Background

Oxidized forms of low-density lipoproteins (ox-LDL)-associated endothelial dysfunction and subsequent monocyte adhesion play an important role in the development of atherosclerosis (AS). Bezafibrate (BEZ) is a peroxisome proliferator-activated receptor (pan-PPAR) agonist licensed as a hypolipidemic drug. However, the effects of BEZ on endothelial dysfunction are less reported.

Objectives

In this study, we aim to investigate the protective effects of BEZ on ox-LDL-challenged vascular endothelial cells to evaluate its potential value in treating AS.

Methods

Human aortic endothelial cells (HAECs) and THP-1 cells were used to establish an In Vitro AS model. Cell Counting Kit-8 (CCK-8) assay, Real-time PCR, Western blot analysis, and Enzyme-linked immunosorbent assay (ELISA) were used to test the data.

Results

As expected, treatment with BEZ suppressed the expression of vascular endothelial growth factor A (VEGF-A), tissue factor (TF), Interleukin 12 (IL-12), tumor necrosis factor (TNF-α), and monocyte chemoattractant protein-1 (MCP-1). BEZ was also found to inhibit ox-LDL-induced expression of the endothelial adhesion molecules vascular cellular adhesion molecule-1 (VCAM-1) and intercellular adhesion molecule-1 (ICAM-1) in HAECs. Correspondingly, BEZ prevented attachment of THP-1 monocytes to ox-LDL-incubated HAECs. Mechanically, BEZ was found to prevent NF-κB activation by reducing the levels of nuclear NF-κB p65 and inhibiting luciferase activity of NF-κB.

Conclusion

Our study revealed the pharmacological function of BEZ in protecting endothelial dysfunction against ox-LDL, which may provide valuable insight for the clinical application of BEZ.

背景:与氧化形式的低密度脂蛋白(ox-LDL)相关的内皮功能障碍和随后的单核细胞粘附在动脉粥样硬化(AS)的发展中起着重要作用。贝扎贝特(Bezafibrate,BEZ)是一种过氧化物酶体增殖体激活受体(pan-PPAR)激动剂,已被许可作为降血脂药物。然而,有关 BEZ 对内皮功能障碍的影响的报道较少:方法:使用人主动脉内皮细胞(HAECs)和 THP-1 细胞建立体外 AS 模型。方法:用人主动脉内皮细胞(HAECs)和THP-1细胞建立体外强直性脊柱炎模型,采用细胞计数试剂盒-8(CCK-8)检测、实时PCR、Western印迹分析和酶联免疫吸附试验(ELISA)检测数据:正如预期的那样,BEZ能抑制血管内皮生长因子A(VEGF-A)、组织因子(TF)、白细胞介素12(IL-12)、肿瘤坏死因子(TNF-α)和单核细胞趋化蛋白-1(MCP-1)的表达。研究还发现,BEZ 能抑制氧化-LDL 诱导的 HAECs 内皮粘附分子血管细胞粘附分子-1(VCAM-1)和细胞间粘附分子-1(ICAM-1)的表达。相应地,BEZ 能阻止 THP-1 单核细胞附着在氧化-LDL 诱导的 HAECs 上。通过降低核 NF-κB p65 的水平和抑制 NF-κB 的荧光素酶活性,BEZ 被发现能从机制上阻止 NF-κB 的活化:我们的研究揭示了 BEZ 保护内皮功能障碍免受 ox-LDL 影响的药理作用,这可能会为 BEZ 的临床应用提供有价值的启示。
{"title":"Bezafibrate mitigates oxidized-low density lipoprotein (ox-LDL)-induced the attachment of monocytes to endothelial cells: An implication in atherosclerosis","authors":"Huijun Huang,&nbsp;Yan Shen","doi":"10.1111/fcp.13025","DOIUrl":"10.1111/fcp.13025","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Oxidized forms of low-density lipoproteins (ox-LDL)-associated endothelial dysfunction and subsequent monocyte adhesion play an important role in the development of atherosclerosis (AS). Bezafibrate (BEZ) is a peroxisome proliferator-activated receptor (pan-PPAR) agonist licensed as a hypolipidemic drug. However, the effects of BEZ on endothelial dysfunction are less reported.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>In this study, we aim to investigate the protective effects of BEZ on ox-LDL-challenged vascular endothelial cells to evaluate its potential value in treating AS.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Human aortic endothelial cells (HAECs) and THP-1 cells were used to establish an In Vitro AS model. Cell Counting Kit-8 (CCK-8) assay, Real-time PCR, Western blot analysis, and Enzyme-linked immunosorbent assay (ELISA) were used to test the data.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>As expected, treatment with BEZ suppressed the expression of vascular endothelial growth factor A (VEGF-A), tissue factor (TF), Interleukin 12 (IL-12), tumor necrosis factor (TNF-α), and monocyte chemoattractant protein-1 (MCP-1). BEZ was also found to inhibit ox-LDL-induced expression of the endothelial adhesion molecules vascular cellular adhesion molecule-1 (VCAM-1) and intercellular adhesion molecule-1 (ICAM-1) in HAECs. Correspondingly, BEZ prevented attachment of THP-1 monocytes to ox-LDL-incubated HAECs. Mechanically, BEZ was found to prevent NF-κB activation by reducing the levels of nuclear NF-κB p65 and inhibiting luciferase activity of NF-κB.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Our study revealed the pharmacological function of BEZ in protecting endothelial dysfunction against ox-LDL, which may provide valuable insight for the clinical application of BEZ.</p>\u0000 </section>\u0000 </div>","PeriodicalId":12657,"journal":{"name":"Fundamental & Clinical Pharmacology","volume":null,"pages":null},"PeriodicalIF":2.1,"publicationDate":"2024-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141619727","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The protective effect of pregabalin and xanthenone on testicular ischemia/reperfusion injury in rats. 普瑞巴林和香丹酮对大鼠睾丸缺血再灌注损伤的保护作用
IF 2.1 4区 医学 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2024-07-08 DOI: 10.1111/fcp.13027
Maha M Abdel-Fattah, Ahmed Mamdouh Ahmed, Rabeh Khairy Saleh, Basim Anwar Shehata Messiha, Remon Roshdy Rofaeil

Background: Torsion of the spermatic cord is a hazardous and common urologic issue. The current work evaluates the possible protective effect of pregabalin (PGB) and xanthenone (XAN) in testicular ischemia/reperfusion injury induced by testicular torsion/detorsion in rats.

Materials and methods: Seven groups of adult male Wistar albino rats were allocated randomly into seven groups, namely, sham control, torsion/detorsion (T/D), PGB 50 mg/kg, PGB 100 mg/kg, XAN 1 mg/kg, XAN 2 mg/kg, and PGB 50 mg/kg plus XAN 1 mg/kg groups. Serum cholesterol and testosterone levels were determined. Also, the levels of malondialdehyde (MDA), reduced glutathione (GSH), nitric oxide (NO), superoxide dismutase (SOD), tumor necrosis factor-α (TNF-α), nuclear factor kappa B (NF-қB), angiotensin (Ang) II, Ang-(1-7), and angiotensin-converting enzyme2 (ACE2) were assessed in testicular tissue. Immunohistochemical analysis of heme oxygenase-1 (HO-1) and caspase-3 was performed. Finally, the histopathological examination of the testicular tissues was performed.

Results: The PGB 50 mg/kg, PGB 100 mg/kg, XAN 1 mg/kg, XAN 2 mg/kg, and PGB 50 mg/kg plus XAN 1 mg/kg groups showed a significant decrease in serum cholesterol, MDA, NO, TNF-α, NF-қB, and Ang-II levels coupled with a significant increase in both testosterone and ACE2 expression. Furthermore, all test groups showed a significant improvement in the histopathological picture with a reduction in caspase-3 and an increase in HO-1 immunoexpression in testicular tissue.

Conclusion: PGB and XAN may have promising effects on preventing testicular T/D injury through antioxidant, anti-inflammatory, and antiapoptotic actions.

背景:精索扭转是泌尿科常见的危险问题。本研究评估了普瑞巴林(PGB)和安体舒通(XAN)对大鼠睾丸扭转/离体诱导的睾丸缺血/再灌注损伤可能具有的保护作用:将7组成年雄性Wistar白化大鼠随机分为7组,即假性对照组、扭转/离体(T/D)组、PGB 50 mg/kg组、PGB 100 mg/kg组、XAN 1 mg/kg组、XAN 2 mg/kg组和PGB 50 mg/kg加XAN 1 mg/kg组。测定了血清胆固醇和睾酮水平。此外,还评估了睾丸组织中丙二醛(MDA)、还原型谷胱甘肽(GSH)、一氧化氮(NO)、超氧化物歧化酶(SOD)、肿瘤坏死因子-α(TNF-α)、核因子卡巴B(NF-қB)、血管紧张素(Ang)II、Ang-(1-7)和血管紧张素转换酶2(ACE2)的水平。对血红素加氧酶-1(HO-1)和Caspase-3进行了免疫组化分析。最后,对睾丸组织进行了组织病理学检查:结果:PGB 50 mg/kg组、PGB 100 mg/kg组、XAN 1 mg/kg组、XAN 2 mg/kg组和PGB 50 mg/kg加XAN 1 mg/kg组的血清胆固醇、MDA、NO、TNF-α、NF-қB和Ang-II水平显著下降,睾酮和ACE2的表达显著增加。此外,所有试验组的组织病理学状况都有明显改善,睾丸组织中的 Caspase-3 减少,HO-1 免疫表达增加:结论:PGB 和 XAN 可通过抗氧化、抗炎和抗细胞凋亡作用预防睾丸 T/D 损伤。
{"title":"The protective effect of pregabalin and xanthenone on testicular ischemia/reperfusion injury in rats.","authors":"Maha M Abdel-Fattah, Ahmed Mamdouh Ahmed, Rabeh Khairy Saleh, Basim Anwar Shehata Messiha, Remon Roshdy Rofaeil","doi":"10.1111/fcp.13027","DOIUrl":"https://doi.org/10.1111/fcp.13027","url":null,"abstract":"<p><strong>Background: </strong>Torsion of the spermatic cord is a hazardous and common urologic issue. The current work evaluates the possible protective effect of pregabalin (PGB) and xanthenone (XAN) in testicular ischemia/reperfusion injury induced by testicular torsion/detorsion in rats.</p><p><strong>Materials and methods: </strong>Seven groups of adult male Wistar albino rats were allocated randomly into seven groups, namely, sham control, torsion/detorsion (T/D), PGB 50 mg/kg, PGB 100 mg/kg, XAN 1 mg/kg, XAN 2 mg/kg, and PGB 50 mg/kg plus XAN 1 mg/kg groups. Serum cholesterol and testosterone levels were determined. Also, the levels of malondialdehyde (MDA), reduced glutathione (GSH), nitric oxide (NO), superoxide dismutase (SOD), tumor necrosis factor-α (TNF-α), nuclear factor kappa B (NF-қB), angiotensin (Ang) II, Ang-(1-7), and angiotensin-converting enzyme2 (ACE2) were assessed in testicular tissue. Immunohistochemical analysis of heme oxygenase-1 (HO-1) and caspase-3 was performed. Finally, the histopathological examination of the testicular tissues was performed.</p><p><strong>Results: </strong>The PGB 50 mg/kg, PGB 100 mg/kg, XAN 1 mg/kg, XAN 2 mg/kg, and PGB 50 mg/kg plus XAN 1 mg/kg groups showed a significant decrease in serum cholesterol, MDA, NO, TNF-α, NF-қB, and Ang-II levels coupled with a significant increase in both testosterone and ACE2 expression. Furthermore, all test groups showed a significant improvement in the histopathological picture with a reduction in caspase-3 and an increase in HO-1 immunoexpression in testicular tissue.</p><p><strong>Conclusion: </strong>PGB and XAN may have promising effects on preventing testicular T/D injury through antioxidant, anti-inflammatory, and antiapoptotic actions.</p>","PeriodicalId":12657,"journal":{"name":"Fundamental & Clinical Pharmacology","volume":null,"pages":null},"PeriodicalIF":2.1,"publicationDate":"2024-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141558636","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Mechanism research on microRNA-669f-5p/deoxycytidylate deaminase axis mediating sevoflurane-induced cognitive dysfunction in aged mice. 微RNA-669f-5p/脱氧胞苷酸脱氨酶轴介导七氟醚诱导老年小鼠认知功能障碍的机制研究
IF 2.1 4区 医学 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2024-07-04 DOI: 10.1111/fcp.13023
Yuan-Ping Zhong, Chao Zhang, Xue Zheng, Dong-Qin Chen, Xu Fang, Yu Zhang, Zhao-Qiong Zhu

Objective: To investigate the role of the microRNA (miRNA)-669f-5p/deoxycytidylate deaminase (Dctd) axis in sevoflurane inducing cognitive dysfunction in aged mice.

Methods: Sixty-six C57BL/6J mice were used in the experiment model and were randomly divided into the sevoflurane group and the control group. The mice in the sevoflurane group were anesthetised with 3.4% sevoflurane, whereas those in the control group were air-treated for the same period. The study was then performed using bioinformatics sequencing, as well as in vitro and in vivo validation.

Results: The mice in the sevoflurane group showed significant cognitive impairments in terms of a decrease in both spatial learning and memory abilities. Experimental doses of miR-669f-5p agonist exhibited no obvious effect on cognitive function following sevoflurane inhalation, but inhibiting the expression of miR-669f-5p could alleviate the impairments. Based on the results of the bioinformatics sequencing, miR-669f-5p/Dctd and the toll-like receptor (TLR) signalling pathway could be the key miRNA, gene and pathway leading to postoperative cognitive dysfunction following sevoflurane inhalation. The aged mice showed significantly increased expression of miR-669f-5p in the hippocampus following sevoflurane inhalation, and upregulating/inhibiting its expression could increase/decrease TLR expression in the hippocampus. Furthermore, miR-669f-5p could reduce the expression of the Dctd gene by binding to its 3'untranslated region.

Conclusion: The miR-669f-5p/Dctd axis plays an important role in sevoflurane inducing cognitive dysfunction in aged mice, providing a new direction for further development of therapeutic strategies concerning the prevention and treatment of cognitive dysfunction associated with sevoflurane anaesthesia.

目的研究微RNA(miRNA)-669f-5p/脱氧胞苷酸脱氨酶(Dctd)轴在七氟烷诱导老年小鼠认知功能障碍中的作用:将66只C57BL/6J小鼠随机分为七氟烷组和对照组。七氟醚组的小鼠使用 3.4% 的七氟醚进行麻醉,而对照组的小鼠则在相同时间内进行空气处理。研究随后进行了生物信息学测序以及体外和体内验证:结果:七氟烷组小鼠的认知能力明显受损,空间学习和记忆能力均下降。实验剂量的 miR-669f-5p 激动剂对小鼠吸入七氟烷后的认知功能无明显影响,但抑制 miR-669f-5p 的表达可减轻小鼠的认知功能障碍。根据生物信息学测序的结果,miR-669f-5p/Dctd和toll样受体(TLR)信号通路可能是导致吸入七氟醚后认知功能障碍的关键miRNA、基因和通路。吸入七氟烷后,老年小鼠海马中的miR-669f-5p表达明显增加,上调/抑制其表达可增加/减少海马中的TLR表达。此外,miR-669f-5p 可通过与 Dctd 基因的 3'untranslated 区域结合来降低该基因的表达:结论:miR-669f-5p/Dctd轴在七氟烷诱导老年小鼠认知功能障碍的过程中发挥了重要作用,为进一步开发预防和治疗七氟烷麻醉相关认知功能障碍的治疗策略提供了新方向。
{"title":"Mechanism research on microRNA-669f-5p/deoxycytidylate deaminase axis mediating sevoflurane-induced cognitive dysfunction in aged mice.","authors":"Yuan-Ping Zhong, Chao Zhang, Xue Zheng, Dong-Qin Chen, Xu Fang, Yu Zhang, Zhao-Qiong Zhu","doi":"10.1111/fcp.13023","DOIUrl":"https://doi.org/10.1111/fcp.13023","url":null,"abstract":"<p><strong>Objective: </strong>To investigate the role of the microRNA (miRNA)-669f-5p/deoxycytidylate deaminase (Dctd) axis in sevoflurane inducing cognitive dysfunction in aged mice.</p><p><strong>Methods: </strong>Sixty-six C57BL/6J mice were used in the experiment model and were randomly divided into the sevoflurane group and the control group. The mice in the sevoflurane group were anesthetised with 3.4% sevoflurane, whereas those in the control group were air-treated for the same period. The study was then performed using bioinformatics sequencing, as well as in vitro and in vivo validation.</p><p><strong>Results: </strong>The mice in the sevoflurane group showed significant cognitive impairments in terms of a decrease in both spatial learning and memory abilities. Experimental doses of miR-669f-5p agonist exhibited no obvious effect on cognitive function following sevoflurane inhalation, but inhibiting the expression of miR-669f-5p could alleviate the impairments. Based on the results of the bioinformatics sequencing, miR-669f-5p/Dctd and the toll-like receptor (TLR) signalling pathway could be the key miRNA, gene and pathway leading to postoperative cognitive dysfunction following sevoflurane inhalation. The aged mice showed significantly increased expression of miR-669f-5p in the hippocampus following sevoflurane inhalation, and upregulating/inhibiting its expression could increase/decrease TLR expression in the hippocampus. Furthermore, miR-669f-5p could reduce the expression of the Dctd gene by binding to its 3'untranslated region.</p><p><strong>Conclusion: </strong>The miR-669f-5p/Dctd axis plays an important role in sevoflurane inducing cognitive dysfunction in aged mice, providing a new direction for further development of therapeutic strategies concerning the prevention and treatment of cognitive dysfunction associated with sevoflurane anaesthesia.</p>","PeriodicalId":12657,"journal":{"name":"Fundamental & Clinical Pharmacology","volume":null,"pages":null},"PeriodicalIF":2.1,"publicationDate":"2024-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141534178","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Vortioxetine improved schizophrenia-like behavioral deficits in a Poly I:C-induced maternal immune activation model of schizophrenia in rats. 伏替西汀可改善 Poly I:C 诱导的母体免疫激活大鼠精神分裂症模型中类似精神分裂症的行为缺陷。
IF 2.1 4区 医学 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2024-07-04 DOI: 10.1111/fcp.13028
Mehmet Taskiran, Sacide Yildiz Taskiran, Gokhan Unal, Nuh Mehmet Bozkurt, Asuman Golgeli

Background: Several studies provide clear evidence that exposure to various infections during pregnancy are linked with an increased risk for schizophrenia. In preclinical studies, administration of polyinosinic-polycytidylic acid (Poly I:C) in pregnant rodents can induce maternal immune activation leading to impairments in brain function in the offspring.

Objectives: The aim of this study was to investigate the effect of vortioxetine, a multimodal selective serotonin reuptake inhibitor (SSRI), in the pathophysiology of Poly I:C-induced schizophrenia-like model in rats.

Methods: For this purpose, Poly I:C (8 mg/kg, ip) was injected into pregnant animals 14 days after mating, and tail blood was taken for determination of IL-6 levels after 2 h. At postnatal days 83-86, behavioral tests were performed.

Results: Our results revealed that Poly I:C caused impairments in prepulse inhibition, novel object recognition, social interaction, and open-field tests. Chronic administration of vortioxetine (2.5, 5, and 10 mg/kg, ip, postnatal days 69-83) caused significant improvements in these deficits.

Conclusion: Overall, our findings indicate that vortioxetine may provide new therapeutic approaches for the treatment of schizophrenia. We think that increased serotonergic activity in frontal brain regions may provide the ameliorative effect of vortioxetine, especially on negative and cognitive symptoms. Therefore, it will be useful to determine the efficacy of vortioxetine with combined drugs with further studies.

背景:多项研究清楚地表明,孕期受到各种感染与精神分裂症风险的增加有关。在临床前研究中,妊娠啮齿动物服用多聚肌苷酸(Poly I:C)可诱发母体免疫激活,导致后代大脑功能受损:本研究旨在探讨多模式选择性5-羟色胺再摄取抑制剂(SSRI)伏替西汀对Poly I:C诱导的大鼠精神分裂症样模型病理生理学的影响:为此,在交配 14 天后向妊娠动物注射 Poly I:C(8 毫克/千克,ip),2 小时后抽取尾血测定 IL-6 水平,并在出生后第 83-86 天进行行为测试:结果:我们的研究结果表明,Poly I:C会导致动物在前脉冲抑制、新物体识别、社会交往和开阔地测试中出现障碍。长期服用伏替西汀(2.5、5和10毫克/千克,ip,出生后第69-83天)可显著改善这些缺陷:总之,我们的研究结果表明,伏替西汀可能为精神分裂症的治疗提供新的治疗方法。我们认为,额叶脑区血清素能活动的增加可能会使伏替西汀产生改善作用,尤其是对阴性症状和认知症状。因此,进一步的研究将有助于确定伏替西汀与联合药物的疗效。
{"title":"Vortioxetine improved schizophrenia-like behavioral deficits in a Poly I:C-induced maternal immune activation model of schizophrenia in rats.","authors":"Mehmet Taskiran, Sacide Yildiz Taskiran, Gokhan Unal, Nuh Mehmet Bozkurt, Asuman Golgeli","doi":"10.1111/fcp.13028","DOIUrl":"https://doi.org/10.1111/fcp.13028","url":null,"abstract":"<p><strong>Background: </strong>Several studies provide clear evidence that exposure to various infections during pregnancy are linked with an increased risk for schizophrenia. In preclinical studies, administration of polyinosinic-polycytidylic acid (Poly I:C) in pregnant rodents can induce maternal immune activation leading to impairments in brain function in the offspring.</p><p><strong>Objectives: </strong>The aim of this study was to investigate the effect of vortioxetine, a multimodal selective serotonin reuptake inhibitor (SSRI), in the pathophysiology of Poly I:C-induced schizophrenia-like model in rats.</p><p><strong>Methods: </strong>For this purpose, Poly I:C (8 mg/kg, ip) was injected into pregnant animals 14 days after mating, and tail blood was taken for determination of IL-6 levels after 2 h. At postnatal days 83-86, behavioral tests were performed.</p><p><strong>Results: </strong>Our results revealed that Poly I:C caused impairments in prepulse inhibition, novel object recognition, social interaction, and open-field tests. Chronic administration of vortioxetine (2.5, 5, and 10 mg/kg, ip, postnatal days 69-83) caused significant improvements in these deficits.</p><p><strong>Conclusion: </strong>Overall, our findings indicate that vortioxetine may provide new therapeutic approaches for the treatment of schizophrenia. We think that increased serotonergic activity in frontal brain regions may provide the ameliorative effect of vortioxetine, especially on negative and cognitive symptoms. Therefore, it will be useful to determine the efficacy of vortioxetine with combined drugs with further studies.</p>","PeriodicalId":12657,"journal":{"name":"Fundamental & Clinical Pharmacology","volume":null,"pages":null},"PeriodicalIF":2.1,"publicationDate":"2024-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141497845","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The β2-adrenergic receptor agonist formoterol attenuates necrosis and apoptosis in the rat myocardium under experimental stress-induced cardiac injury. β2-肾上腺素能受体激动剂福莫特罗能减轻大鼠心肌在实验应激诱导的心脏损伤中的坏死和凋亡。
IF 2.1 4区 医学 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2024-07-02 DOI: 10.1111/fcp.13026
Natalia V Naryzhnaya, Sergey V Logvinov, Boris K Kurbatov, Ivan A Derkachev, Liliia R Mustafina, Aleksandr S Gorbunov, Maria A Sirotina, Mikhail Kilin, Svetlana V Gusakova, Leonid N Maslov

Background: Currently, there is no effective therapy for takotsubo syndrome (stress-induced cardiac injury in humans) in the clinics. It has previously been shown that β2-adrenergic receptor (β2-AR) agonist formoterol reduces cardiomyocyte injury in experimental takotsubo syndrome.

Objectives: The aim of this study was to investigate whether formoterol prevents apoptosis and necrosis of cardiomyocytes and endothelial cells in stress-induced cardiomyopathy.

Methods: Stress-induced cardiac injury was induced by immobilization of rats for 2, 6, and 24 hours.

Results: The myocardium of stressed rats showed a reduction in contractility and histological manifestations of cardiomyocyte damage: karyopyknosis, perinuclear edema of cardiomyocytes and endothelial cells, and microcirculation disturbances augmented with extended exposure to stress. In addition, apoptosis of endothelial cells was detected 6 hours after the onset of stress and peaked at 24 hours. Apoptosis of cardiomyocytes significantly gained only after 24 hours of stress exposure. These morphological alterations were associated with increased levels of serum creatine kinase-MB, syndecan-1, and thrombomodulin after 24 hours of stress. Administration of β2-AR agonist formoterol (50 μg/kg) four times during 24-hour stress exposure led to the improvement in myocardial inotropy, decrease in the severity of histological signatures, reduction in the number of TUNEL-positive cardiomyocytes, serum creatine kinase-MB, syndecan-1, and thrombomodulin levels.

Conclusion: Present data suggest that apoptosis and necrosis of cardiomyocytes and necrosis of endothelial cells in stress-induced cardiac injury can be mitigated by activation of the β2-AR. However, formoterol did not eliminate completely cardiomyocyte apoptosis, histological alterations, or endothelium injury markers under stress.

背景:目前,临床上还没有治疗拓扑综合征(应激诱发的人类心脏损伤)的有效疗法。之前有研究表明,β2-肾上腺素能受体(β2-AR)激动剂福莫特罗能减轻实验性拓扑综合征的心肌细胞损伤:本研究旨在探讨福莫特罗是否能预防应激诱导的心肌病中心肌细胞和内皮细胞的凋亡和坏死:方法:将大鼠固定2、6和24小时,诱发应激性心肌损伤:结果:应激大鼠的心肌显示出收缩力下降和心肌细胞损伤的组织学表现:核分裂、心肌细胞和内皮细胞的核周水肿以及微循环障碍随着应激时间的延长而加剧。此外,在应激开始 6 小时后检测到内皮细胞凋亡,并在 24 小时后达到高峰。心肌细胞的凋亡仅在应激暴露 24 小时后才显著增加。这些形态学改变与应激 24 小时后血清肌酸激酶-MB、辛迪加-1 和血栓调节蛋白水平的升高有关。在24小时应激暴露期间,给予β2-AR激动剂福莫特罗(50 μg/kg)四次,可改善心肌肌力,降低组织学特征的严重程度,减少TUNEL阳性心肌细胞的数量,降低血清肌酸激酶-MB、辛迪卡-1和血栓调节蛋白的水平:目前的数据表明,在应激诱导的心脏损伤中,心肌细胞的凋亡和坏死以及内皮细胞的坏死可通过激活β2-AR得到缓解。然而,福莫特罗并不能完全消除应激下的心肌细胞凋亡、组织学改变或内皮损伤标志物。
{"title":"The β<sub>2</sub>-adrenergic receptor agonist formoterol attenuates necrosis and apoptosis in the rat myocardium under experimental stress-induced cardiac injury.","authors":"Natalia V Naryzhnaya, Sergey V Logvinov, Boris K Kurbatov, Ivan A Derkachev, Liliia R Mustafina, Aleksandr S Gorbunov, Maria A Sirotina, Mikhail Kilin, Svetlana V Gusakova, Leonid N Maslov","doi":"10.1111/fcp.13026","DOIUrl":"https://doi.org/10.1111/fcp.13026","url":null,"abstract":"<p><strong>Background: </strong>Currently, there is no effective therapy for takotsubo syndrome (stress-induced cardiac injury in humans) in the clinics. It has previously been shown that β<sub>2</sub>-adrenergic receptor (β<sub>2</sub>-AR) agonist formoterol reduces cardiomyocyte injury in experimental takotsubo syndrome.</p><p><strong>Objectives: </strong>The aim of this study was to investigate whether formoterol prevents apoptosis and necrosis of cardiomyocytes and endothelial cells in stress-induced cardiomyopathy.</p><p><strong>Methods: </strong>Stress-induced cardiac injury was induced by immobilization of rats for 2, 6, and 24 hours.</p><p><strong>Results: </strong>The myocardium of stressed rats showed a reduction in contractility and histological manifestations of cardiomyocyte damage: karyopyknosis, perinuclear edema of cardiomyocytes and endothelial cells, and microcirculation disturbances augmented with extended exposure to stress. In addition, apoptosis of endothelial cells was detected 6 hours after the onset of stress and peaked at 24 hours. Apoptosis of cardiomyocytes significantly gained only after 24 hours of stress exposure. These morphological alterations were associated with increased levels of serum creatine kinase-MB, syndecan-1, and thrombomodulin after 24 hours of stress. Administration of β<sub>2</sub>-AR agonist formoterol (50 μg/kg) four times during 24-hour stress exposure led to the improvement in myocardial inotropy, decrease in the severity of histological signatures, reduction in the number of TUNEL-positive cardiomyocytes, serum creatine kinase-MB, syndecan-1, and thrombomodulin levels.</p><p><strong>Conclusion: </strong>Present data suggest that apoptosis and necrosis of cardiomyocytes and necrosis of endothelial cells in stress-induced cardiac injury can be mitigated by activation of the β<sub>2</sub>-AR. However, formoterol did not eliminate completely cardiomyocyte apoptosis, histological alterations, or endothelium injury markers under stress.</p>","PeriodicalId":12657,"journal":{"name":"Fundamental & Clinical Pharmacology","volume":null,"pages":null},"PeriodicalIF":2.1,"publicationDate":"2024-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141491684","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Sodium-glucose cotransporter-2 inhibitor (SGLT2i) plus glucagon-like peptide type 1 receptor combination is more effective than SGLT2i plus dipeptidyl peptidase-4 inhibitor combination in treating obese mice metabolic dysfunction-associated steatotic liver disease (MASLD). 钠-葡萄糖共转运体-2 抑制剂(SGLT2i)加胰高血糖素样肽 1 型受体组合比 SGLT2i 加二肽基肽酶-4 抑制剂组合治疗肥胖小鼠代谢功能障碍相关性脂肪性肝病(MASLD)更有效。
IF 2.1 4区 医学 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2024-06-24 DOI: 10.1111/fcp.13024
Pedro H Reis-Barbosa, Carlos A Mandarim-de-Lacerda

Background: Monotherapy to treat obesity-associated liver insult is limited.

Objectives: In diet-induced obese mice showing metabolic dysfunction-associated steatotic liver disease (MASLD), we aimed to compare the combinations of sodium-glucose cotransporter-2 inhibitor (SGLT2i, empagliflozin, E), dipeptidyl peptidase-4 inhibitor (DPP4i, linagliptin, L), and glucagon-like peptide type 1 receptor agonist (GLP1RA, dulaglutide, D).

Methods: Male 3-month-old C57BL/6J mice were fed for 12 weeks in a control (C, n = 10) or high-fat (HF, n = 30) diet. Then, mice were followed for three additional weeks: C, HF, HF E + L, and HF E + D (n = 10/group).

Results: HF versus C showed higher hepatic triacylglycerol (TAG, +82%), steatosis (+850%), glucose intolerance (+71%), insulin (+98%), and insulin resistance (+68%). Compared to the HF group, HF E + L showed lower glucose intolerance (-60%), insulin (-61%), insulin resistance (-46%), TAG (-61%), and steatosis (-58%), and HF E + D showed lower glucose intolerance (-71%), insulin (-58%), insulin resistance (-62%), TAG (-61%), and steatosis (-82%). The principal component analysis (PCA) placed the HF group and the HF E + D group on opposite sides, while the HF E + L group was placed between C and HF E + D.

Conclusion: PCA separated the groups considering the metabolism-related genes (glucose and lipid), mitochondrial biogenesis, and steatosis. The two pharmacological combinations showed beneficial effects in treating obesity and MASLD. However, the combination of SGLT2i and GLP1RA showed more potent beneficial effects on MASLD than SGLT2i and DPP4i and, therefore, should be the recommended combination.

背景治疗肥胖相关性肝损伤的单一疗法非常有限:在饮食诱导的出现代谢功能障碍相关脂肪性肝病(MASLD)的肥胖小鼠中,我们旨在比较钠-葡萄糖共转运体-2抑制剂(SGLT2i,empagliflozin,E)、二肽基肽酶-4抑制剂(DPP4i,linagliptin,L)和胰高血糖素样肽1型受体激动剂(GLP1RA,dulaglutide,D)的组合:雄性 3 个月大 C57BL/6J 小鼠以对照组(C,n = 10)或高脂组(HF,n = 30)饮食喂养 12 周。然后,再对小鼠进行为期三周的跟踪观察:结果:结果:HF 组与 C 组相比,肝脏三酰甘油(TAG,+82%)、脂肪变性(+850%)、葡萄糖不耐受(+71%)、胰岛素(+98%)和胰岛素抵抗(+68%)均较高。与高频组相比,高频 E + L 组的糖耐量减低(-60%)、胰岛素减低(-61%)、胰岛素抵抗减低(-46%)、TAG 减低(-61%)和脂肪变性减低(-58%),而高频 E + D 组的糖耐量减低(-71%)、胰岛素减低(-58%)、胰岛素抵抗减低(-62%)、TAG 减低(-61%)和脂肪变性减低(-82%)。主成分分析(PCA)将高频组和高频 E + D 组置于两侧,而高频 E + L 组则位于 C 组和高频 E + D 组之间:PCA对代谢相关基因(葡萄糖和脂质)、线粒体生物生成和脂肪变性进行了分组。两种药物组合在治疗肥胖症和 MASLD 方面显示出有益的效果。然而,与 SGLT2i 和 DPP4i 相比,SGLT2i 和 GLP1RA 的组合对 MASLD 有更强的疗效,因此应作为推荐组合。
{"title":"Sodium-glucose cotransporter-2 inhibitor (SGLT2i) plus glucagon-like peptide type 1 receptor combination is more effective than SGLT2i plus dipeptidyl peptidase-4 inhibitor combination in treating obese mice metabolic dysfunction-associated steatotic liver disease (MASLD).","authors":"Pedro H Reis-Barbosa, Carlos A Mandarim-de-Lacerda","doi":"10.1111/fcp.13024","DOIUrl":"https://doi.org/10.1111/fcp.13024","url":null,"abstract":"<p><strong>Background: </strong>Monotherapy to treat obesity-associated liver insult is limited.</p><p><strong>Objectives: </strong>In diet-induced obese mice showing metabolic dysfunction-associated steatotic liver disease (MASLD), we aimed to compare the combinations of sodium-glucose cotransporter-2 inhibitor (SGLT2i, empagliflozin, E), dipeptidyl peptidase-4 inhibitor (DPP4i, linagliptin, L), and glucagon-like peptide type 1 receptor agonist (GLP1RA, dulaglutide, D).</p><p><strong>Methods: </strong>Male 3-month-old C57BL/6J mice were fed for 12 weeks in a control (C, n = 10) or high-fat (HF, n = 30) diet. Then, mice were followed for three additional weeks: C, HF, HF E + L, and HF E + D (n = 10/group).</p><p><strong>Results: </strong>HF versus C showed higher hepatic triacylglycerol (TAG, +82%), steatosis (+850%), glucose intolerance (+71%), insulin (+98%), and insulin resistance (+68%). Compared to the HF group, HF E + L showed lower glucose intolerance (-60%), insulin (-61%), insulin resistance (-46%), TAG (-61%), and steatosis (-58%), and HF E + D showed lower glucose intolerance (-71%), insulin (-58%), insulin resistance (-62%), TAG (-61%), and steatosis (-82%). The principal component analysis (PCA) placed the HF group and the HF E + D group on opposite sides, while the HF E + L group was placed between C and HF E + D.</p><p><strong>Conclusion: </strong>PCA separated the groups considering the metabolism-related genes (glucose and lipid), mitochondrial biogenesis, and steatosis. The two pharmacological combinations showed beneficial effects in treating obesity and MASLD. However, the combination of SGLT2i and GLP1RA showed more potent beneficial effects on MASLD than SGLT2i and DPP4i and, therefore, should be the recommended combination.</p>","PeriodicalId":12657,"journal":{"name":"Fundamental & Clinical Pharmacology","volume":null,"pages":null},"PeriodicalIF":2.1,"publicationDate":"2024-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141456294","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Population pharmacokinetics of mycophenolate in patients treated for interstitial lung disease (EVER-ILD study) 间质性肺病患者中霉酚酸酯的群体药代动力学(EVER-ILD 研究)。
IF 2.1 4区 医学 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2024-06-16 DOI: 10.1111/fcp.13021
Yan-Min Xu, David Ternant, Martine Reynaud-Gaubert, Théodora Bejan-Angoulvant, Sylvain Marchand-Adam

Background

Mycophenolate mofetil (MMF) has been used to treat interstitial lung disease (ILD), but mycophenolate (MPA) pharmacokinetics was not reported for this use. This ancillary study of the EVER-ILD protocol aimed at describing the pharmacokinetic variability of MPA using population modelling in ILD.

Methods

Concentrations of MPA were measured during an 8-h course for 27 ILD patients treated with 1000 mg MMF b.i.d. Absorption, distribution and elimination of MPA were described using population compartment models with first-order transfer and elimination rate constants, while accounting for both absorption peaks using gamma absorption models.

Results

The pharmacokinetics of MPA was best described using a two-compartment model and two gamma absorption models, model performances of this model were still similar to those of a one gamma absorption model. This pharmacokinetics seemed to be notably influenced by body weight, renal function and inflammatory status. The distribubtion value area under the concentration curve between two administrations of MMF was AUC12 = 52.5 mg.h/L in median (interquartile range: 42.2–58.0 mg.h/L).

Conclusion

This is the first study reporting MPA pharmacokinetics in ILD. This pharmacokinetics appears to be similar to other indications and should be further investigated in future studies.

背景:霉酚酸酯(MMF)已被用于治疗间质性肺病(ILD),但霉酚酸酯(MPA)的药代动力学尚未见报道。这项EVER-ILD方案的辅助研究旨在利用群体模型描述MPA在ILD中的药代动力学变异性:采用具有一阶转移和消除速率常数的群体分区模型来描述 MPA 的吸收、分布和消除,同时采用伽马吸收模型来考虑两个吸收峰:结果:采用两室模型和两个伽马吸收模型对 MPA 的药代动力学进行了最佳描述,该模型的性能仍与单伽马吸收模型相似。这种药代动力学似乎明显受到体重、肾功能和炎症状态的影响。MMF两次给药之间的浓度曲线下分布值的中位数为AUC12 = 52.5 mg.h/L(四分位间范围:42.2-58.0 mg.h/L):结论:这是第一项报道MPA在ILD中药代动力学的研究。结论:这是第一项报告 MPA 在 ILD 中药代动力学的研究,该药代动力学似乎与其他适应症相似,应在今后的研究中进一步探讨。
{"title":"Population pharmacokinetics of mycophenolate in patients treated for interstitial lung disease (EVER-ILD study)","authors":"Yan-Min Xu,&nbsp;David Ternant,&nbsp;Martine Reynaud-Gaubert,&nbsp;Théodora Bejan-Angoulvant,&nbsp;Sylvain Marchand-Adam","doi":"10.1111/fcp.13021","DOIUrl":"10.1111/fcp.13021","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Mycophenolate mofetil (MMF) has been used to treat interstitial lung disease (ILD), but mycophenolate (MPA) pharmacokinetics was not reported for this use. This ancillary study of the EVER-ILD protocol aimed at describing the pharmacokinetic variability of MPA using population modelling in ILD.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Concentrations of MPA were measured during an 8-h course for 27 ILD patients treated with 1000 mg MMF b.i.d. Absorption, distribution and elimination of MPA were described using population compartment models with first-order transfer and elimination rate constants, while accounting for both absorption peaks using gamma absorption models.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The pharmacokinetics of MPA was best described using a two-compartment model and two gamma absorption models, model performances of this model were still similar to those of a one gamma absorption model. This pharmacokinetics seemed to be notably influenced by body weight, renal function and inflammatory status. The distribubtion value area under the concentration curve between two administrations of MMF was AUC<sub>12</sub> = 52.5 mg.h/L in median (interquartile range: 42.2–58.0 mg.h/L).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>This is the first study reporting MPA pharmacokinetics in ILD. This pharmacokinetics appears to be similar to other indications and should be further investigated in future studies.</p>\u0000 </section>\u0000 </div>","PeriodicalId":12657,"journal":{"name":"Fundamental & Clinical Pharmacology","volume":null,"pages":null},"PeriodicalIF":2.1,"publicationDate":"2024-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/fcp.13021","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141330720","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pharmacological treatment for mental health illnesses in adults receiving dialysis: A scoping review 接受透析治疗的成人精神疾病的药物治疗:范围综述。
IF 2.1 4区 医学 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2024-06-15 DOI: 10.1111/fcp.13022
Jenny Wichart, Peter Yoeun, Tracy Chin, Christopher Evernden, Charlotte Berendonk, Jodi Kerr, Alexandra Birchall, Belinda Boschee, Kimberly Defoe, Jasleen Dhaliwal, Tasia KarisAllen, Megan Kennedy, Alexis McDonald, Monika K. Mierzejewski, Kara Schick-Makaroff

Background

Pharmacologic management of mental health illnesses in patients receiving dialysis is complex and lacking data.

Objective

Our objective was to synthesize published data for the treatment of depression, bipolar and related disorders, schizophrenia or psychotic disorders, and anxiety disorders in adults receiving hemodialysis or peritoneal dialysis.

Methods

We undertook a scoping review, searching the following databases: Medline, Embase, CINAHL, PsycINFO, Cochrane Library, Scopus, and Web of Science. Data on patients who received only short-term dialysis, a kidney transplant, or non-pharmacologic treatments were excluded.

Results

Seventy-three articles were included: 41 focused on depression, 16 on bipolar disorder, 13 on schizophrenia and psychotic disorders, 1 on anxiety disorders, and 2 addressing multiple mental health illnesses. The majority of depression studies reported on selective serotonin reuptake inhibitors (SSRIs) as a treatment. Sertraline had the most supporting data with use of doses from 25 to 200 mg daily. Among the remaining SSRIs, escitalopram, citalopram, and fluoxetine were studied in controlled trials, whereas paroxetine and fluvoxamine were described in smaller reports and observational trials. There are limited published data on other classes of antidepressants and on pharmacological management of anxiety. Data on treatment for patients with bipolar disorder or schizophrenia and related disorders are limited to case reports.

Conclusion

Over half of the studies included were case reports, thus limiting conclusions. More robust data are required to establish effect sizes of pharmacological treatments prior to providing specific recommendations for their use in treating mental health illnesses in patients receiving dialysis.

背景:透析患者精神疾病的药物治疗非常复杂且缺乏数据:我们的目的是综合已发表的有关治疗接受血液透析或腹膜透析的成人抑郁症、双相情感障碍和相关障碍、精神分裂症或精神病性障碍以及焦虑症的数据:我们对以下数据库进行了范围界定研究Medline、Embase、CINAHL、PsycINFO、Cochrane Library、Scopus 和 Web of Science。仅接受短期透析、肾移植或非药物治疗的患者的数据被排除在外:结果:共收录了 73 篇文章:41篇侧重于抑郁症,16篇侧重于躁郁症,13篇侧重于精神分裂症和精神病,1篇侧重于焦虑症,2篇涉及多种精神疾病。大多数抑郁症研究报告都将选择性血清素再摄取抑制剂(SSRIs)作为一种治疗方法。舍曲林的支持性数据最多,每日使用剂量从 25 毫克到 200 毫克不等。在其余的 SSRIs 中,艾司西酞普兰、西酞普兰和氟西汀是在对照试验中研究的,而帕罗西汀和氟伏沙明则是在较小的报告和观察试验中描述的。关于其他类别的抗抑郁药和焦虑症的药物治疗,已发表的数据十分有限。关于治疗双相情感障碍或精神分裂症及相关疾病患者的数据仅限于病例报告:结论:半数以上的研究为病例报告,因此限制了结论的得出。在对透析患者的精神疾病治疗提出具体建议之前,需要更多可靠的数据来确定药物治疗的效果大小。
{"title":"Pharmacological treatment for mental health illnesses in adults receiving dialysis: A scoping review","authors":"Jenny Wichart,&nbsp;Peter Yoeun,&nbsp;Tracy Chin,&nbsp;Christopher Evernden,&nbsp;Charlotte Berendonk,&nbsp;Jodi Kerr,&nbsp;Alexandra Birchall,&nbsp;Belinda Boschee,&nbsp;Kimberly Defoe,&nbsp;Jasleen Dhaliwal,&nbsp;Tasia KarisAllen,&nbsp;Megan Kennedy,&nbsp;Alexis McDonald,&nbsp;Monika K. Mierzejewski,&nbsp;Kara Schick-Makaroff","doi":"10.1111/fcp.13022","DOIUrl":"10.1111/fcp.13022","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Pharmacologic management of mental health illnesses in patients receiving dialysis is complex and lacking data.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>Our objective was to synthesize published data for the treatment of depression, bipolar and related disorders, schizophrenia or psychotic disorders, and anxiety disorders in adults receiving hemodialysis or peritoneal dialysis.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We undertook a scoping review, searching the following databases: Medline, Embase, CINAHL, PsycINFO, Cochrane Library, Scopus, and Web of Science. Data on patients who received only short-term dialysis, a kidney transplant, or non-pharmacologic treatments were excluded.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Seventy-three articles were included: 41 focused on depression, 16 on bipolar disorder, 13 on schizophrenia and psychotic disorders, 1 on anxiety disorders, and 2 addressing multiple mental health illnesses. The majority of depression studies reported on selective serotonin reuptake inhibitors (SSRIs) as a treatment. Sertraline had the most supporting data with use of doses from 25 to 200 mg daily. Among the remaining SSRIs, escitalopram, citalopram, and fluoxetine were studied in controlled trials, whereas paroxetine and fluvoxamine were described in smaller reports and observational trials. There are limited published data on other classes of antidepressants and on pharmacological management of anxiety. Data on treatment for patients with bipolar disorder or schizophrenia and related disorders are limited to case reports.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Over half of the studies included were case reports, thus limiting conclusions. More robust data are required to establish effect sizes of pharmacological treatments prior to providing specific recommendations for their use in treating mental health illnesses in patients receiving dialysis.</p>\u0000 </section>\u0000 </div>","PeriodicalId":12657,"journal":{"name":"Fundamental & Clinical Pharmacology","volume":null,"pages":null},"PeriodicalIF":2.1,"publicationDate":"2024-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/fcp.13022","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141320834","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Fundamental & Clinical Pharmacology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1